Welcome : Guest

Bellerophon Therapeutics, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Bellerophon Therapeutics, Inc., which is principally involved in Clinical-Stage Therapeutics Business. Illustrated with 14 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-63851
Price: $700
Company Type: Public
Pages: 16
Date: November 2016
Market Data Tables: 14

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
  BELLEROPHON THERAPEUTICS, INC. (USA) (Complete Report)Pages : 16|$ 700.00
1. COMPANY SNIPPETS......1
2. COMPETITION BY DIVISION......2
3. MARKET OVERVIEW......3
Pulmonary Arterial Hypertension (PAH)......3
Table 1: Pulmonary Arterial Hypertension (PAH) Treatment by Drug Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Adcirca, Letairis/Volibris, Remodulin, Revatio, Tracleer, Tyvaso and Ventavis......3
Table 2: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy Worldwide (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......4
Table 3: Pulmonary Arterial Hypertension (PAH) Treatment with Macitentan Drug by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Japan, US and Rest of World......5
Table 4: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......6
Table 5: Pulmonary Arterial Hypertension (PAH) Treatment by Type Worldwide (2015) - Percentage Breakdown by Value for Inhaled Prostacyclins, Orals (ERAs, PDE5s, Prostacyclins), and Parenteral Prostacyclins......7
Table 6: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in Europe (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......8
Table 7: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in Europe (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......9
Table 8: Pulmonary Arterial Hypertension Treatment Market by Product Segment in Japan (2015) - Percentage Share Breakdown by Value for Adcirca, Dorner, Flolan, Procylin, Revatio, and Tracleer......10
Table 9: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in the US (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......11
Table 10: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in the US (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......12
Chronic Obstructive Pulmonary Disease (COPD) Drugs......13
Table 11: Chronic Obstructive Pulmonary Disease (COPD) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for Europe, North America and Rest of the World......13
Table 12: Chronic Obstructive Pulmonary Disease (COPD) Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Long Acting Muscarinic Antagonists (LAMA), Long Acting Muscarinic Antagonists (LAMA) and Long Acting β2-Agonists (LABA), and Long Acting β2-Agonists (LABA) and Inhaled Corticosteroid (ICS)......14
Table 13: No. of Chronic Obstructive Pulmonary Disease (COPD) Patients Worldwide (2015) - Percentage Market Share Breakdown for Europe, North America, and Rest of World......15
Table 14: Chronic Obstructive Pulmonary Disease (COPD) and Asthma Market by Product Worldwide (2015) - Percentage Share Breakdown by Value for Flixotide and Flovent, Seretide and Advair, Spiriva, Symbicort, Xolair, and Others......16